You are here

Our science / Clinical Trials / Find a Trial / NCT00895050

Study Evaluating Impact of the Use of a Computer-based Tool on the Clinical Management of RA Patients

Back to Search Print Save as PDF Bookmark Trial

NCT00895050

Last updated on March 31, 2020
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Rheumatoid Arthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

Main Inclusion Criteria:

- Patients, male or female, over 18 years old.

- Patients diagnosed with RA according to investigator criteria

- Patients with a disease evolution >= 1 year

- Patients with > = 5 affected joints

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

Exclusion Criteria:

- Patients with other muscle skeletal, rheumatic and/or degenerative diseases different
from RA.

- Patients who are taking part or have taken part in a clinical trial or in a study with
drugs within the last 12 months. Any condition that, in the investigator's judgment
would interfere with the subject's ability to comply with protocol requirements or
give informed consent.

NCT00895050
Pfizer
Completed
Study Evaluating Impact of the Use of a Computer-based Tool on the Clinical Management of RA Patients

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Advanced Search

Based on your search, you may also be interested in

Rheumatoid Arthritis
A Comparative Study Between PF-06410293 and Humira® in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis
NCT04230213
All Genders
18+
Years
Multiple Sites
Rheumatoid Arthritis
Observational Study to Determine How Physicians Make Treatment Decisions in Patients Treated With Tofacitinib for Moderate to Severe Active Rheumatoid Arthritis
NCT03387423
All Genders
18+
Years
Multiple Sites
Rheumatoid Arthritis
IDentification of Factors Predictive of Tofacitinib's Survival in Patient With Rheumatoid Arthritis
NCT03981900
All Genders
18+
Years
Multiple Sites
Systemic Lupus Erythematosus, Rheumatoid Arthritis
Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis
NCT03334851
All Genders
18+
Years
Multiple Sites
Descriptive Information
Brief Title Study Evaluating Impact of the Use of a Computer-based Tool on the Clinical Management of RA Patients
Official Title Impact of the Use of a Computer-based Tools on the Clinical Management and Evolution of Patients With Rheumatoid Arthritis.
Brief Summary The primary purpose of this study is to evaluate a computer-based tool on the clinical management of patients with rheumatoid arthritis in Spain.
Detailed Description Not Provided
Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population Patients with RA treated in rheumatology offices
Condition Rheumatoid Arthritis
Intervention Other: Review of clinical records
Study Groups/Cohorts 1
Patients diagnosed with RA
Intervention: Other: Review of clinical records
Publications * Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: July 13, 2011) 		321
Original Estimated Enrollment
 (submitted: May 6, 2009) 		300
Actual Study Completion Date January 2011
Actual Primary Completion Date January 2011   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

Main Inclusion Criteria:

  • Patients, male or female, over 18 years old.
  • Patients diagnosed with RA according to investigator criteria
  • Patients with a disease evolution >= 1 year
  • Patients with > = 5 affected joints

Exclusion Criteria:

Exclusion Criteria:

  • Patients with other muscle skeletal, rheumatic and/or degenerative diseases different from RA.
  • Patients who are taking part or have taken part in a clinical trial or in a study with drugs within the last 12 months. Any condition that, in the investigator's judgment would interfere with the subject's ability to comply with protocol requirements or give informed consent.
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Not Provided
Removed Location Countries Spain
 
Administrative Information
NCT Number NCT00895050
Other Study ID Numbers 0881X1-4576
B1801084
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Director, Clinical Trial Disclosure Group, Pfizer, Inc
Study Sponsor Pfizer
Collaborators Not Provided
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
PRS Account Pfizer
Verification Date July 2011

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now